

Ref:21-066	Received: 17 February 2021	Issued: 9 March 2021
------------	----------------------------	----------------------

First and second line treatments

What is first line and second line treatment for patients with a diagnosis of relapsing remitting MS (RRMS)?

First line in RRMS would be INFB, Glatiramer, Tecfidera, Teriflunomide, (now possibly ozanimod), second line Fingolimod, Tysabri, Cladribine, Ocrelizumab, Natalizumab

What is first line and second line treatment for patients with a diagnosis of primary progressive MS (PPMS)?

First line for PP none - in the future Ocrevus

What is first line and second line treatment for patients with a diagnosis of secondary progressive MS (SPMS)?

First line for SP MS: siponimod for active disease

DMT use and costs

Please complete Table 1.

Table 1: Use of DMTs in 2020

Drug	No of patients treated with this drug in 2020	Total cost of the treatment
Alemtuzumab (Lemtrada)	0	
Avonex (interferon beta-1a)	7	
interferon alpha	0	
interferon beta	<5	
Cladribine (Mavenclad)	<5	
Daclizumab (Zinbryta) - withdrawn	Not in data	
Dimethyl fumarate (Tecfidera)	65	
Extavia (beta interferon-1b)	Not in data	
Fingolimod (Gilenya)	33	
Glatiramer acetate (Copaxone)	7	
Natalizumab (Tysabri)	28	
Ocrelizumab (Ocrevus)	<5	
Peginterferon alpha	0	
Plegridy (peginterferon beta 1a)	12	
Rebif (beta interferon-1a)	<5	

Costs have not been given as the cost of these drugs is commercially sensitive information; therefore this information is exempt under section 33 of FOISA.

In addition less than five replaces the actual data as this could potentially identify individuals and is exempt under section 38(1)(b) of FOISA.

Prevalence of MS

Table 2: Prevalence of types of MS

	Number of patients with diagnosis
RRMS	
PPMS	
SPMS	
Other types of MS	
Total	

This data is not held in a reportable format; therefore this request is refused under section 17 of FOISA.